ProMIS Q2 net loss $2.3M; cash drops to $1.2M; PMN310 IND cleared

ProMIS Neurosciences Inc.

2023-Q2 EPS reported -$0.85

Net loss $2.3M vs $2.7M YoY; R&D expense fell to $1.0M from $3.2M.
Cash and equivalents $1.2M at June 30, 2023, down from $5.9M at Dec 31, 2022.
PMN310 received FDA IND clearance in May 2023; Phase 1a planned subject to capital.
Preclinical data at AAIC 2023 showed PMN310 selectively targets toxic amyloid beta oligomers with potential for improved safety.
Shares delisted from TSX in July 2023; now trades solely on Nasdaq.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ProMIS Neurosciences Inc. reported the second quarter ended June 30, 2023 results: net income Net loss was $2.3 million for the quarter ended June 30, 2023.

Period: the second quarter ended June 30, 2023
Net income: Net loss was $2.3 million for the quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 14, 2023, ProMIS Neurosciences Inc. (the "Company") issued a press release, which is available on its website (www.promisneurosciences.com under “Investors/Financial Results”), reporting its financial condition and financial results as of and for the three and six months ended June 30, 2023.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

ProMIS Neurosciences Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-014916

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.